• VX-702: A Practical p38α MAPK Inhibitor Guide

  2026-09-17

  VX-702 provides a selective way to connect p38α MAPK target engagement with cytokine, platelet, arthritis, and cardiac injury readouts. This workflow-focused guide covers solution handling, assay design, mechanistic validation, and troubleshooting for inflammation and rheumatoid arthritis research.

• DGLA–ACSL4 Ferroptosis in Acute Myeloid Leukemia

  2026-09-16

  The reference study shows that exogenous dihomo-γ-linolenic acid (DGLA) promotes ferroptosis in acute myeloid leukemia cells through ACSL4-dependent lipid metabolic reprogramming. Its combination of targeted metabolomics, genetic disruption, cell-based testing, and dietary validation identifies fatty-acid handling as a potential route for addressing apoptosis-resistant AML, while still requiring broader translational validation.

• Anti Reverse Cap Analog for Metabolic mRNA Studies

  2026-09-16

  Anti Reverse Cap Analog (ARCA), 3´-O-Me-m7G(5')ppp(5')G supports directional mRNA capping when researchers need strong, transient protein expression in metabolic and cell-engineering assays. This article translates the TCAIM–OGDH findings into practical mRNA workflow choices while separating product-backed performance from proposed experimental extensions.

• ASB3-MAVS Regulation of Antiviral Immunity

  2026-09-15

  The 2024 reference study identifies ASB3 as an E3 ligase that suppresses antiviral innate immunity by promoting K48-linked ubiquitination and proteasomal degradation of MAVS at K297. Its gain- and loss-of-function, infection, mechanistic, and animal experiments connect ASB3 activity with reduced interferon signaling and greater susceptibility to influenza virus, while also defining practical readouts for studying this pathway.

• Flubendazole Workflows for Autophagy Assays

  2026-09-15

  Build more informative Flubendazole experiments by separating growth inhibition from cell killing and pairing viability with autophagy readouts. This practical workflow covers DMSO handling, time-resolved assay design, comparative analysis, and troubleshooting for cancer biology research.

• Roscovitine (Seliciclib) Workflow Guide

  2026-09-14

  Build more interpretable cell-cycle and cancer biology assays with Roscovitine (Seliciclib), using dose response, reversible washout, orthogonal readouts, and careful solvent controls. The workflow also shows how to place this multi-CDK probe within compact, data-driven small-molecule panels rather than treating one phenotypic result as proof of a single target.

• Microfluidic Peptide/RNA Complexes for Lung Delivery

  2026-09-14

  The reference study developed a controllable microfluidic method for preparing LAH4-L1 or PEG12KL4 complexes with siRNA or mRNA, followed by aerosolisation with a vibrating mesh nebuliser. Its key finding was that inhalable aerosols with aerodynamic diameters below 5 μm could be generated while RNA binding and in vitro transfection activity remained comparable after nebulisation.

• SU5416 and the HIF1α–VEGFR2 Translational Axis

  2026-09-13

  SU5416 (Semaxanib) is best understood not only as a VEGFR2 inhibitor, but as a mechanistic probe for how oxygen sensing, vascular metabolism, endothelial signaling, and immune regulation converge. This thought-leadership guide connects recent HIF1α findings with practical experimental design for angiogenesis, tumor biology, and vascular research.

• Cy5-UTP for Axonal RNA Imaging

  2026-09-12

  Cy5-UTP converts T7 RNA polymerase transcription into a direct, far-red RNA detection workflow for FISH, transport mapping, and multiplex assays. Applied to the axonal trafficking problem, it helps distinguish RNA localization from downstream protein-aggregation phenotypes without relying on post-staining.

• Cimetidine in BBB and Cancer Research Workflows

  2026-09-11

  Cimetidine offers a differentiated research tool for connecting H2 receptor biology with reproducible barrier-permeability and gastrointestinal cancer assays. This workflow-focused guide shows how to manage solubility, distinguish transport from intracellular trapping, and interpret its partial-agonist pharmacology without treating it as a conventional H2 blocker.

• Arginine Methylation in FUS–SMN Phase Separation

  2026-09-11

  Wang and Li show that asymmetric dimethylarginine modification enables FUS to engage oligomeric SMN and form phase-separated neuronal granules. The study connects methylation-dependent multivalency with axonal mRNA distribution and neuronal function, while identifying SMN oligomerization as a disease-relevant determinant of granule assembly.

• OSMI-1: O-GlcNAc Transferase Inhibitor Guide

  2026-09-10

  OSMI-1 is a cell-permeable O-GlcNAc transferase inhibitor with a reported biochemical IC50 of 2.7 μM. It reduces protein O-GlcNAcylation and provides a research tool for testing OGT-dependent mechanisms, including pathways relevant to trophoblast ferroptosis.

• DiR (DiIC 18 (7)) for EV Tracking Assays

  2026-09-10

  DiR (DiIC 18 (7)) is more than a membrane stain: it can help design spatial and temporal assays for extracellular vesicle biodistribution. This article explains how to use its near-infrared signal while avoiding common errors in interpreting membrane-associated fluorescence as proof of intact vesicle delivery.

• PD0325901 Workflows for MEK Signaling Research

  2026-09-09

  PD0325901 provides a controllable way to connect MEK inhibition with P-ERK loss, cell-cycle remodeling, apoptosis, and xenograft response. This workflow also shows how findings on O-GlcNAcylation and galectin-3 can improve assay selection without overstating cross-domain evidence.

• DiR (DiIC 18 (7)) for Reliable Cell Tracking

  2026-09-09

  Learn how DiR (DiIC 18 (7)) and SKU B8806 can strengthen membrane tracking, live-cell imaging, and orthogonal interpretation of viability or cytotoxicity assays. This scenario-based guide covers compatibility, formulation, controls, data interpretation, and practical vendor selection.

8308 records 1/554 page Next 12345 下5页 Last page